Canakinumab 100mg [clinicaltrials_resource:NCT00819585/group/E3]
Canakinumab 100 mg s.c. once at Day 1, placebo s.c. at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg- 300 mg) for 24 weeks.
Total, other adverse events for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/32/count/220]Diarrhoea for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/33/count/227]Nausea for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/34/count/234]Nasopharyngitis for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/35/count/241]Upper respiratory tract infection for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/36/count/248]Alanine aminotransferase increased for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/37/count/255]Aspartate aminotransferase increased for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/38/count/262]Arthralgia for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/39/count/269]Back pain for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/40/count/276]Headache for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/41/count/283]Sinus congestion for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/42/count/290]Rash for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/43/count/297]Hypertension for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/other_events/44/count/304]Total, serious adverse events for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/1/count/3]Cholelithiasis for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/10/count/66]Ear infection for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/11/count/73]Erysipelas for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/12/count/80]Gangrene for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/13/count/87]Pneumonia for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/14/count/94]Sepsis for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/15/count/101]Tonsillitis for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/16/count/108]Femur fracture for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/17/count/115]Hand fracture for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/18/count/122]Ligament rupture for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/19/count/129]Acute myocardial infarction for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/2/count/10]Radius fracture for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/20/count/136]Tibia fracture for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/21/count/143]Ulna fracture for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/22/count/150]Osteoarthritis for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/23/count/157]Tendonitis for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/24/count/164]Prostate cancer for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/25/count/171]Renal cancer for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/26/count/178]Stupor for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/27/count/185]Haematuria for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/28/count/192]Nephrolithiasis for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/29/count/199]Angina pectoris for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/3/count/17]Nephrotic syndrome for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/30/count/206]Renal failure for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/31/count/213]Myocardial infarction for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/4/count/24]Abdominal pain for NCT00819585 for E3 in NCT00819585 [clinicaltrials_resource:NCT00819585/serious_events/5/count/31]
group [clinicaltrials_vocabulary:group]
Canakinumab 100mg [clinicaltrials_resource:NCT00819585/group/E3]
Canakinumab 100 mg s.c. once at Day 1, placebo s.c. at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg- 300 mg) for 24 weeks.
Bio2RDF identifier
NCT00819585/group/E3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00819585/group/E3
group id [clinicaltrials_vocabulary:group-id]
description
Canakinumab 100 mg s.c. once a ...... (100 mg- 300 mg) for 24 weeks.
@en
identifier
clinicaltrials_resource:NCT00819585/group/E3
title
Canakinumab 100mg
@en
type
label
Canakinumab 100mg [clinicaltrials_resource:NCT00819585/group/E3]
@en